MacroGenics (MGNX) Set to Announce Quarterly Earnings on Thursday

MacroGenics (NASDAQ:MGNX) will announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.49). MacroGenics had a negative net margin of 15.42% and a negative return on equity of 88.49%. The company had revenue of $10.72 million during the quarter, compared to analyst estimates of $25.70 million. During the same quarter in the prior year, the business earned $0.21 EPS. On average, analysts expect MacroGenics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Price Performance

Shares of MacroGenics stock opened at $16.05 on Wednesday. The firm has a market capitalization of $1.00 billion, a P/E ratio of -100.31 and a beta of 2.09. The company’s 50 day moving average price is $16.43 and its two-hundred day moving average price is $12.59. MacroGenics has a fifty-two week low of $4.29 and a fifty-two week high of $21.88.

Analyst Ratings Changes

MGNX has been the subject of a number of analyst reports. Barclays lifted their target price on shares of MacroGenics from $12.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. TD Cowen raised shares of MacroGenics from a “hold” rating to a “buy” rating in a research note on Tuesday, April 9th. TheStreet downgraded shares of MacroGenics from a “c” rating to a “d” rating in a research note on Thursday, March 7th. B. Riley started coverage on shares of MacroGenics in a research note on Friday, April 26th. They issued a “buy” rating and a $25.00 price target for the company. Finally, JMP Securities reaffirmed a “market outperform” rating on shares of MacroGenics in a research note on Thursday, April 4th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.00.

Insider Buying and Selling

In other MacroGenics news, VP Jeffrey Stuart Peters sold 51,395 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $15.55, for a total value of $799,192.25. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 11.30% of the stock is owned by corporate insiders.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.